Ammar Rasoul Mohammad¹, Ekhlas Sabah Hassan², Huda Sabah Hassen³

[pvc_stats postid=\\\”\\\” increase=\\\”1\\\” show_views_today=\\\”0\\\”]

¹Assistant Professor Clinical Oncologist, Department of Pharmacology and Therapeutics, Faculty of Medicine, University of Kufa, Iraq.
²Assistant Professor Internal Medicine, Department of Pharmacology and Therapeutics, Faculty of Medicine, University of Kufa, Iraq.
²Assistant Professor, Department of Chemistry, Faculty of Education for Girls, University of Kufa, Iraq.

[sdm_download_counter id=\\\”8721\\\”]

https://doi.org/10.47721/ARJB202101011

Vol 3(1&2), pp. 1-9, June 2021

Copyright © 2021 Author(s) and Skies Educational.
This article is published under the terms of the Creative Commons Attribution License 4.0

[sdm_download id=\\\”8721\\\” fancy=\\\”0\\\”]

ABSTRACT

Hypofractionated whole breast irradiation (HF-WBI), which means the utilization of daily doses of radiation more than 2.0 Gy, is a broadly examined technique for delivering radiotherapy as a component of breast-conserving strategy after lumpectomy for early-stage breast cancer and utilization of hypofractionated radiotherapy has been expanding around the world. In any case, numerous radiation oncologists still oppose the normal appropriation of hypofractionated radiotherapy. HF-WBI has been demonstrated successful, safe and superior for late or acute radiation toxicity for early breast cancer. Additionally, it enhances patient convenience, quality of life and is expected to be advantageous in the therapeutic consideration framework by decreasing overall cost. Two all-encompassing inquiries emerge: In which patients is it appropriate to receive hypofractionated radiation? What are the societal advantages of hypofractionated radiation? Hypofractionated radiotherapy ought to be routinely offered to ladies who want breast-conserving surgery with invasive node-negative breast cancer paying little mind to the grade of invasive disease. Further national appropriation of hypofractionated radiotherapy can conceivably spare the healthcare system billions of dollars over the coming years and in addition, enhance the convenience of breast-conserving radiotherapy and decreasing the workload on linear accelerator machines and increase the number of patients who are getting radiotherapy.

Keywords: Breast, hypofractionated radiation, radiotherapy.

REFERENCES

1. Wang SL, Fang H, Song YW, Wang WH, et al. Hypofractionated versus conventional fractionated postmastectomy radiotherapy for patients with high-risk breast cancer: a randomised, non-inferiority, open-label, phase 3 trial. Lancet Oncol. 2019 Mar;20(3):352-360.
2. Owen JR, Ashton A, Bliss JM, et al. Effect of radiotherapy fraction size on tumour control in patients with early-stage breast cancer after local tumour excision: long-term results of a randomised trial. Lancet Oncol. 2006 Jun;7(6):467-71.
3. Shaitelman SF, Lei X, Thompson A, et al. Three-Year Outcomes With Hypofractionated Versus Conventionally Fractionated Whole-BreastIrradiation: Results of a Randomized, Non-inferiority Clinical Trial. J Clin Oncol. 2018 Oct 31.
4. Haviland JS, Owen JR, Dewar JA, et al. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10- year follow-up results of two randomised controlled trials. Lancet Oncol 2013;14:1086-94.
5. Owen JR, Ashton A, Bliss JM, et al. Effect of radiotherapy fraction size on tumour control in patients with early-stage breast cancer after local tumour excision: long-term results of a randomised trial. Lancet Oncol 2006;7:467-71.
6. Zhao S, Liu Y, Huang F, et al. The long-term outcome of adjuvant hypofractionated radiotherapy and conventionally fractionated radiotherapy after breast-conserving surgery for early breast cancer: a prospective analysis of 107 cases. J Thorac Dis. 2017 Oct;9(10):3840-3850.
7. Avanzo M, Trovo M, Stancanello J et al. Hypofractionation of partial breast irradiation using radiobiological models. Phys Med. 2015 Dec;31(8):1022-1028.
8. Smith BD, Bellon JR, Blitzblau R, et al. Radiation therapy for the whole breast: Executive summary of an American Society for Radiation Oncology (ASTRO) evidence-based guideline. Pract Radiat Oncol. 2018 May-June;8(3):145-152.
9. Lee HB, Han W. Unique features of young age breast cancer and its management. J Breast Cancer. 2014 Dec;17(4):301-7. 10. Cho WK, Choi DH, Kim H et al. Adjuvant radiation therapy in small ductal carcinoma in situ Breast. 2018 Nov 9;43:55-58.
10. Cho WK, Choi DH, Kim H et al. Adjuvant radiation therapy in small ductal carcinoma in situ Breast. 2018 Nov 9;43:55-58.
11. Deantonio L, Cozzi S, Tunesi S. Hypofractionated radiation therapy for breast cancer: long-term results in a series of 85 patients.. Tumori. 2016 Aug 3;102(4):398-403.
12. Bellefqih S, Elmajjaoui S, Aarab J, Hypofractionated Regional Nodal Irradiation for Women With Node-Positive Breast Cancer. Int J Radiat Oncol Biol Phys. 2017 Mar 1;97(3):563-570.
13. Ippolito E, Rinaldi CG, Silipigni S. Hypofractionated radiotherapy with concomitant boost for breast cancer: a dose-escalation study. Br J Radiol. 2018 Nov 28:20180169
14. Whelan TJ, Pignol JP, Levine MN et al. Long-term results of hypofractionated radiation therapy for breast cancer. N. Engl. J. Med. 362(6), 513–520 (2010).
15. De Rose F, Fogliata A, Franceschini D, et al. Hypofractionation with a simultaneous boost in breast cancer patients receiving adjuvant chemotherapy: A prospective evaluation of a case series and review of the literature. Breast. 2018 Aug 22;42:31-37.
16. Hathout L, Hijal T, Théberge V,et al. Hypofractionated radiation therapy for breast ductal carcinoma in situ. Int J Radiat Oncol Biol Phys. 2013 Dec 1;87(5):1058-63.
17. Parekh A, Dholakia AD, Zabranksy DJ et al. Predictors of radiation-induced acute skin toxicity in breast cancer at a single institution: Role of fractionation and treatment volume. Adv Radiat Oncol. 2017 Nov 6;3(1):8-15.
18. Deantonio L, Gambaro G, Beldì D et al. Hypofractionated radiotherapy after conservative surgery for breast cancer: analysis of acute and late toxicity. Radiat Oncol. 2010 Nov 23;5:112.
19. Reimer T, Gerber B. Quality-of-life considerations in the treatment of early-stage breast cancer in the elderly. Drugs Aging. 2010 Oct 1;27(10):791-800. .
20. Sardar P, Kundu A, Chatterjee S et al. Long-term cardiovascular mortality after radiotherapy for breast cancer: A systematic review and meta-analysis. Clin Cardiol. 2017 Feb;40(2):73-81
21. Doré M, Cutuli B, Cellier P et al. Hypofractionated irradiation in elderly patients with breast cancer after breast-conserving surgery and mastectomy: Analysis of 205 cases. Radiat Oncol. 2015 Aug 4;10:161.
22. Leong N, Truong PT, Tankel K et al. Hypofractionated Nodal Radiation Therapy for Breast Cancer Was Not Associated With Increased Patient-Reported Arm or Brachial Plexopathy Symptoms. Int J Radiat Oncol Biol Phys. 2017 Dec 1;99(5):1166-1172.
23. Rastogi K, Jain S, Bhatnagar AR, Bhaskar S et al. A Comparative Study of Hypofractionated and Conventional Radiotherapy in Postmastectomy Breast Cancer Patients. Asia Pac J Oncol Nurs. 2018 Jan-Mar;5(1):107-113.
24. Holloway CL, Panet-Raymond V, Olivotto I. Hypofractionation should be the new \\\’standard\\\’ for radiation therapy after breast-conserving surgery. Breast. 2010 Jun;19(3):163-7.
25. Diwanji TP, Molitoris JK, Chhabra AM et al. Utilization of hypofractionated whole-breast radiation therapy in patients receiving chemotherapy: a National Cancer Database analysis. Breast Cancer Res Treat. 2017 Sep;165(2):445-453.
26. Hashemi FA, Barzegartahamtan M, Mohammadpour RA, Sebzari A, Kalaghchi B, et al. Comparison of Conventional and Hypofractionated Radiotherapy in Breast Cancer Patients in Terms of 5-Year Survival, Locoregional Recurrence, Late Skin Complications and Cosmetic Results. Asian Pac J Cancer Prev. 2016; 17(11): 4819–4823.
27. Freedman GM. Hypofractionated radiation therapy in the treatment of early-stage breast cancer. Curr Oncol Rep. 2012 Feb;14(1):12-9.

CITATIONS

CrossRef Citation (0)

Google Scholar Citations

AUTHORS

Ammar Rasoul Mohammad is an Assistant Professor, Clinical Oncologist, Department of Pharmacology and Therapeutics, Faculty of Medicine, University of Kufa, Iraq.
Ekhlas Sabah Hassan is an Assistant Professor, Internal Medicine, Department of Pharmacology and Therapeutics, Faculty of Medicine, University of Kufa, Iraq.
Huda Sabah Hassen is an Assistant Professor, Department of Chemistry, Faculty of Education for Girls, University of Kufa, Iraq.

ARTICLE METRICS

CrossRef Article Metrics

HOW TO CITE THIS ARTICLE

Ammar R. M., Ekhlas S. H., and Huda S. H. (2021). Hypofractionated whole breast irradiation in the treatment of patients with early-stage breast cancer. Applied Research Journal of Biotechnology, 3(1&2), 1-9. https://doi.org/10.47721/ARJB202101011